Invention Grant
- Patent Title: VEGFR-2 targeting DNA vaccine for combination therapy
-
Application No.: US15737659Application Date: 2016-06-16
-
Publication No.: US10905752B2Publication Date: 2021-02-02
- Inventor: Heinz Lubenau
- Applicant: VAXIMM AG
- Applicant Address: CH Basel
- Assignee: VAXIMM AG
- Current Assignee: VAXIMM AG
- Current Assignee Address: CH Basel
- Agency: Dentons US LLP
- Priority: EP15001803 20150618
- International Application: PCT/EP2016/001004 WO 20160616
- International Announcement: WO2016/202459 WO 20161222
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/39 ; A61K39/395 ; A61K35/74 ; A61P35/00 ; A61P37/06 ; A61K45/06

Abstract:
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
Public/Granted literature
- US20180250345A1 VEGFR-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY Public/Granted day:2018-09-06
Information query